Antineoplastics
1
Reactions 1316 - 28 Aug 2010 S Antineoplastics Various toxicities: 3 case reports In a study, three patients developed various toxicities during chemotherapy including erlotinib, gemcitabine, cisplatin and carboplatin for non-small cell lung cancer [routes and dosages not stated]. A 71-year-old woman commenced erlotinib, and subsequently developed GI toxicity and an intense rash [time to reaction onset not stated]. Erlotinib was reduced to 100mg and her symptoms partially resolved. After 5 months of treatment, her disease progressed and she died. A 53-year-old woman developed haematological toxicity after receiving one cycle of gemcitabine and cisplatin. She was then administered one cycle of gemcitabine and carboplatin, with recurrence of haematological toxicity [outcome not stated]. Further chemotherapy consisted of gefitinib, but she subsequently died of disease progression. A 51-year-old man initiated chemotherapy with gemcitabine and cisplatin, but developed haematological toxicity and an allergic reaction after one cycle [outcome not stated]. Further chemotherapy included erlotinib, but his disease progressed and he died. Author comment: The authors identified an additional two patients who received chemotherapy for NSCLC, but these patients did not developed ADRs. Benesova L, et al. Multiplicity of EGFR and KRAS mutations in Non-small Cell Lung Cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Research 30: 1667-1671, May 2010 - Czech Republic 803035781 1 Reactions 28 Aug 2010 No. 1316 0114-9954/10/1316-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1316 - 28 Aug 2010
SAntineoplastics
Various toxicities: 3 case reportsIn a study, three patients developed various toxicities
during chemotherapy including erlotinib, gemcitabine,cisplatin and carboplatin for non-small cell lung cancer[routes and dosages not stated].
A 71-year-old woman commenced erlotinib, andsubsequently developed GI toxicity and an intense rash[time to reaction onset not stated]. Erlotinib was reduced to100mg and her symptoms partially resolved. After5 months of treatment, her disease progressed and shedied.
A 53-year-old woman developed haematological toxicityafter receiving one cycle of gemcitabine and cisplatin. Shewas then administered one cycle of gemcitabine andcarboplatin, with recurrence of haematological toxicity[outcome not stated]. Further chemotherapy consisted ofgefitinib, but she subsequently died of disease progression.
A 51-year-old man initiated chemotherapy withgemcitabine and cisplatin, but developed haematologicaltoxicity and an allergic reaction after one cycle [outcomenot stated]. Further chemotherapy included erlotinib, buthis disease progressed and he died.
Author comment: The authors identified an additionaltwo patients who received chemotherapy for NSCLC, butthese patients did not developed ADRs.Benesova L, et al. Multiplicity of EGFR and KRAS mutations in Non-small CellLung Cancer (NSCLC) patients treated with tyrosine kinase inhibitors. AnticancerResearch 30: 1667-1671, May 2010 - Czech Republic 803035781
1
Reactions 28 Aug 2010 No. 13160114-9954/10/1316-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
